2025 Abstracts and Workshop Presentations

Session 1.1 – OMS history and tribute to M Kinsbourne – Andrea Klein

Session 1.2 Abstract – Prognosis treatment and mechanisms in an international pediatric onset opsoclonus myoclonus ataxia syndrome POOMAS study – an update – Mark Gorman and Rebecca MacRae

Session 1.2 – Prognosis treatment and mechanisms in an international pediatric onset opsoclonus myoclonus ataxia syndrome POOMAS study – an update – Mark Gorman and Rebecca MacRae

Session 1.3 Abstract – Opsoclonus Myoclonus Syndrome Dancing Eye Syndrome in Children With and Without Neuroblastoma-NBpos and NBneg-Gudrun Schleiermacher, Benoit Dumont

Session 1.4 Abstract – Adaptive Designs in Rare Diseases OMAS – Gary Cutter

Session 1.4 – Adaptive Designs in Rare Diseases OMAS – Gary Cutter

Session 1.4 – Adaptive Designs in Rare Diseases OMAS – Gary Cutter – Cont.

Session 2.1 Abstract – Vamorolone-Can it be a treatment for OMAS – Tim Lotze and Ming Lim

Session 2.1 – Vamorolone-Can it be a treatment for OMAS – Tim Lotze and Ming Lim

Session 3.1 Abstract – Detection of novel autoantibodies in children with OMS – Thais Armangue

Session 3.3 Abstract – Comprehensive Identification of Novel Autoantibody Candidates in Opsoclonus-Myoclonus Ataxia Syndrome Using Proteome-Wide Screening Platforms – Taisuke Yamauchi

Session 3.3 – Comprehensive Identification of Novel Autoantibody Candidates in Opsoclonus-Myoclonus Ataxia Syndrome Using Proteome-Wide Screening Platforms – Taisuke Yamauchi

Session 3.4 Abstract – Eye tracking and its structural and functional correlates in OMAS – Ann Yeh

Session 3.4 – Eye tracking and its structural and functional correlates in OMAS – Ann Yeh

Session 4.1 Abstract – Children Sleep Habits Prior, During, and After Active OMAS – An Initial Analysis – Yasmin Khakoo and Scott Milligan

Session 4.1 – Children Sleep Habits Prior, During, and After Active OMAS – An Initial Analysis – Yasmin Khakoo

Session 4.1B – Children Sleep Habits Prior, During, and After Active OMAS – An Initial Analysis – Scott Milligan

Session 4.2 Abstract – Development of a real-world evidence (RWE) roadmap to advance OMAS understanding & advocacy- Scott Milligan

Session 4.2 – Development of a real-world evidence (RWE) roadmap to advance OMAS understanding & advocacy- Scott Milligan

Session 4.3 Abstract – Whole Genome Sequencing and HLA typing in OMAS – Mark Gorman and Rebecca MacRae

Session 4.3 – Whole Genome Sequencing and HLA typing in OMAS – Mark Gorman and Rebecca MacRae

Session 4.4 Abstract – Inaugural Findings on OMSLife Registry – Mark Gorman and Mike Michaelis

Session 4.4 – Inaugural Findings on OMSLife Registry – Mark Gorman and Mike Michaelis

Session 5.1 Abstract – Neurodevelopmental outcomes following OMAS An Indian perspective – Naveen Sankhyan

Session 5.1 – Neurodevelopmental outcomes following OMAS An Indian perspective – Naveen Sankhyan

Session 5.2 Abstract – Infections associated OMAS Do we need to approach differently- Naveen Sankhyan

Session 5.2 – Infections associated OMAS Do we need to approach differently- Naveen Sankhyan

Session 5.3 Abstract – Clinical presentation and outcome of OMAS A Brazilian perspective – Renata Paolilo

Session 5.3 – Clinical presentation and outcome of OMAS A Brazilian perspective – Renata Paolilo

Session 5.4 – Clinical presentation and outcome of OMAS A Japanese perspective – Taisuke Yamauchi

Session 6.1 Abstract – Moving Forward in the Neuropsychiatric Care and Neuropsychological Assessment of Individuals with OMAS – Aaron Hauptman and Hannah-Lise Schofield

Session 6.1 – Moving Forward in the Neuropsychiatric Care and Neuropsychological Assessment of Individuals with OMAS – Aaron Hauptman and Hannah-Lise Schofield